AEVIS VICTORIA SA / Key word(s): Acquisition Ad hoc announcement pursuant to Art. 53 LR Fribourg, 12 December 2024 AEVIS VICTORIA SA (AEVS.SW) – AEVIS VICTORIA announces the acquisition of Spital Zofingen by Swiss Medical Network and a strategic partnership with Kantonsspital Aarau AEVIS VICTORIA SA (AEVIS) announces the acquisition of Spital Zofingen, a subsidiary of Kantonsspital Aarau AG (KSA), by Swiss Medical Network Holding SA (SMN), marking an important milestone in its strategy for growth and the development of integrated healthcare in Switzerland. This acquisition, with payment made in SMN shares, paves the way for a strategic partnership between SMN and KSA. KSA becomes a strategic shareholder in SMN, holding 3.57% of the capital, thereby establishing a sustainable collaboration between the two institutions. This transaction confirms the valuation of SMN, consistent with the valuation applied during the capital increase with Visana Beteiligungen. Antoine Hubert, Delegate of the Board of AEVIS, said: “This acquisition fits perfectly into our strategy of broadening Swiss Medical Network’s shareholder base by bringing in top-tier strategic partners. By partnering with Kantonsspital Aarau, we strengthen our commitment to integrated healthcare and consolidate our position in the Swiss healthcare market.” Conference call today at 3 p.m. For further information: AEVIS VICTORIA SA - Investing for a better life End of Inside Information |
2050149 12-Dec-2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.